E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
Irregular and often very fast heart rate |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cardiovascular Diseases [C14] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 19.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10003658 |
E.1.2 | Term | Atrial fibrillation |
E.1.2 | System Organ Class | 10007541 - Cardiac disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Patient-reported quality of life (QoL), with a predefined focus on physical well-being using the SF-36 (a QoL tool) physical component summary at six months. |
|
E.2.2 | Secondary objectives of the trial |
Patient-reported QoL using three separate tools: • SF-36 global and domain-specific scores at 6 and 12 months • EQ-5D-5L summary index and visual analogue scale at six and twelve months • AFEQT overall score at six and twelve months Cardiac function: • Echocardiography at 12 months • Diastolic function at 12 months • Functional assessment: • Six-minute walking distance at 6 and 12 months • Change in European Heart Rhythm Association (EHRA) class at 6 and 12 months Biomarkers: • Change in B-type natriuretic peptide (BNP) levels at 6 months • Change in heart rate using 24-hour ambulatory ECG
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Adult patients aged 60 years or older • Permanent AF, characterised (at time of randomisation) as a physician decision for rate-control with no plans for cardioversion, anti-arrhythmic medication, or ablation therapy • Symptoms of breathlessness (New York Heart Association Class II or more) • Able to provide written informed consent
|
|
E.4 | Principal exclusion criteria |
• Established clinical indication for beta-blocker therapy, e.g. myocardial infarction in the last 6 months • Known contraindications for therapy with beta-blockers or digoxin, e.g. a history of severe bronchospasm that would preclude use of beta-blockers, or known intolerance to these medications • Baseline heart rate <60 bpm • History of second or third-degree heart block • Supraventricular arrhythmias associated with accessory conducting pathways (e.g. Wolff-Parkinson-White syndrome) or a history of ventricular tachycardia or fibrillation • Planned pacemaker implantation (including cardiac resynchronisation therapy), pacemaker-dependent rhythm or history of atrioventricular node ablation • Decompensated heart failure (evidenced by need for intravenous inotropes, vasodilators or diuretics) within 14 days prior to randomisation • A current diagnosis of obstructive hypertrophic cardiomyopathy, myocarditis or constrictive pericarditis • Received or on waiting list for heart transplantation • Receiving renal replacement therapy • Major surgery, including thoracic or cardiac surgery, within 3 months of randomisation • Severe, concomitant non-cardiovascular disease (including malignancy) that is expected to reduce life expectancy
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Patient-reported quality of life (QoL), with a predefined focus on physical well-being using the SF-36 physical component summary at six months. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
Secondary objectives
• Generic and AF-specific patient-reported QoL using the SF-36 global and domain-specific scores, the AFEQT overall score and the EQ-5D-5L summary index and visual analogue scale at six and twelve months. • Echocardiographic left-ventricular ejection fraction (LVEF) and diastolic function (E/e’ and composite of diastolic indices) at twelve months. • Functional assessment, including 6-minute walking distance achieved, change in European Heart Rhythm Association (EHRA) class and cognitive function at six and twelve months. • Change in B-type natriuretic peptide (BNP) levels as a surrogate for total cardiac strain at six months. • Change in heart rate from baseline and group comparison using 24-hour ambulatory ECG.
Feasibility objectives
• Successful methods for recruitment • Key issues that affect retention of participants, such as convenience, compliance and cross-over (target of 85% study completion rate). • Drug discontinuation rate and adverse reactions leading to drug discontinuation. • Therapy-induced requirement for additional treatment (e.g. pacemaker implantation). • Population-specific standard deviations and proportions to enable sample size calculation for a future trial. • Assessment of cardiovascular outcomes including a composite of adverse clinical events (mortality, thromboembolic events, myocardial infarction and cardiovascular interventions).
Exploratory objectives
• Correlation of baseline measures, including QoL questionnaires and unblinded baseline investigations such as QoL, BNP, LVEF, E/e’, EHRA, intracellular methods and heart rate. • Impact of therapy on intracellular sodium and calcium concentration and cardiotonic steroid levels as biomarkers of cellular response at six and twelve months. • Impact of combination therapy on outcomes, including comparison of bisoprolol/non-dihydropyridine calcium channel blocker (CCB) vs. bisoprolol/digoxin vs. digoxin/CCB vs. single therapies. • Change in cognitive function at twelve months • Qualitative research of patient-reported QoL using focus groups to explore patient acceptability, optimal delivery methods and responsiveness. • Assessment of the validity and reproducibility of echocardiographic measures in patients with AF. • Correlation of serum digoxin concentration with change in QoL and intracellular methods. • Cost-consequence economic analysis from an NHS perspective.
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
approximately 2-3 months, 6 and 12 months |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
Pilot - determining feasibility for a future clinical trial (recruitment, retention, sample size) |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
Prospective randomised open-label, blinded endpoint (PROBE) trial |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of the trial will be 30 days after last data capture i.e. 30 days after the date of the last visit of the last patient undergoing the protocol-based therapy. This will allow sufficient time for the completion of protocol procedures, data collection and input. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 0 |